| Fiscal Year End | Company Status | Exempt Flag |
| December 31 | Delist | N |
|
|
|
|
|
| Incorporation Locations |
| Inc. Date | Expiry Date | Country | Region | Description |
| 21/Jan/2000 | 20/Jan/2019 | Canada | Manitoba | The Corporations Act |
|
|
| Exchange Filing Office |
| Location |
| (not available) |
|
|  |
| Business Type(s) |
| Primary/Secondary | Business Type | Details |
| Primary
| *Biotechnology Research &/or Development
| News Release January 20, 2015-DiaMedica is a publicly traded (TSX VENTURE:DMA) development stage biopharmaceutical company primarily focused on large unmet diseases including novel approaches to treat vascular and metabolic diseases. DiaMedica's lead product, DM199, is recombinant human tissue kallikrein-1 protein (rhKLK1).
|
|
|
| Securities |
| Symbol | Security Name | Market | Status |
| *DMA | *Diamedica Therapeutics Inc. | TSX Venture | DELIST |
| *DMA | *Diamedica Therapeutics Inc. Old | TSX Venture | DELIST |
| *DMA | *DiaMedica Inc. | TSX Venture | DELIST |
|
|
| Name History | From | To |
| *DiaMedica Therapeutics Inc. | 29/Dec/2016 | 20/Jan/2019 |
| *DiaMedica Inc. | 21/Jan/2000 | 28/Dec/2016 |
|
|
| Company Facts Reconciliation |
| Subject | Date Returned |
| Spring 2015 CFR | Not Received |
|
|
|
|
|
